Atezolizumab-bevacizumab combination delays quality-of-life deterioration in hepatocellular carcinoma

Atezolizumab in combination with bevacizumab delayed time to deterioration of quality of life, physical functioning and role functioning compared with standard-of-care sorafenib as first-line treatment for unresectable hepatocellular carcinoma, according to patient-reported outcomes of the randomized phase 3 IMbrave 150 study scheduled for presentation at Gastrointestinal Cancers Symposium.
The combination also appeared to delay appetite loss, fatigue, pain and diarrhea.
“Because it reflects both the effects of the disease and the side effects of treatment, sustained or improved quality

Source link

Related posts

A hot topic- how to manage acute liver injury from checkpoint inhibitors


The American Journal of Gastroenterology Presents "The Negative Issue"


ACA turns 10: Experts reflect on the law’s impact on health care


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy